Tuesday Mar 4
ZIOPHARM Oncology Upgraded by Piper Jaffray to Neutral
ZIOPHARM Oncology traded up 8.31% during mid-day trading on Tuesday, hitting $4.56.
ZIOPHARM Reports Fourth-Quarter and Full-Year 2013 Financial Results and Reviews Recent Activities
ZIOPHARM Oncology, Inc. today announced financial results for the fourth quarter and full year ended December 31, 2013 and provided an update on the company's product development activities.
Five Star Equities Issues New Research Reports on CBM, INVN, TQNT and ...
Five Star Equities releases regular market updates so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns.
ZIOPHARM Oncology, Inc. To Present At The 16th Annual Biotechnology...
ZIOPHARM Oncology, Inc. today announced that Jonathan Lewis, M.D., Ph.D., Chief Executive Officer, and Francois Lebel, M.D., Senior Vice President, Clinical Development and Medical Operations, will present at the 16th Annual BIO CEO & Investor Conference on Monday, February 10th, 2014 at 10:00 a.m. ET at the Waldorf Astoria in New York City.